" GERN said it would end development of GRN1005, an experimental brain cancer drug, and plans to undergo a a restructuring that includes cutting its work force by 40%. It also said it plans to replace its chief financial officer."
This is the drug that they were to focus on when they abandoned their stem cell trial.
And there were those who told people, despite the ridiculous trials they had, to "balance" their stem cell investments with money in GERN. Understanding the choices the companies made and why was critical to avoiding that disaster. GERN has been a conventional wisdom disaster, long in the making and the money behind that company has long been in denial.
Shareholders getting it up the keister. I actually sold that pig at $5.52. That was the last good med tech trade in my stable. It’s a shame for people with brain cancer that our government pours all their medical research money into mostly useless college programs, when the true innovators and risk takers drown one after the other.